You are viewing the site in preview mode
Skip to main content
| |
TAs (ng/g)
|
iAsIII%
|
iAsV%
|
MMA%
|
DMA%
|
PMI
|
SMI
|
|---|
|
Plasma
|
|
Patients
|
6.43 ± 1.56
|
11.40 ± 9.98
|
44.47 ± 19.81
|
17.19 ± 13.39
|
24.50 ± 15.47
|
0.25 (0–5.04)
|
1.75 (0.06–37.14)
|
|
Control
|
8.99 ± 1.14
|
33.87 ± 18.92
|
25.26 ± 16.56
|
19.29 ± 14.53
|
16.13 ± 13.03
|
0.28 (0–8.74)
|
0.82 (0–19.2)
|
|
P value
|
< 0.001
|
< 0.001
|
< 0.001
|
0.28
|
< 0.001
|
0.742
|
0.002
|
|
Urine
|
|
Patients
|
45.28 ± 33.28
|
40.08 ± 28.90
|
8.72 ± 11.42
|
15.64 ± 14.05
|
26.36 ± 26.64
|
0.27 (0–5.52)
|
1.21 (0–143.01)
|
|
Control
|
57.55 ± 33.61
|
1.94 ± 7.19
|
1.37 ± 6.31
|
2.49 ± 3.52
|
78.92 ± 18.79
|
0.27 (0–1.24)
|
16.36 (3.32–120.34)
|
|
P value
|
0.009
|
< 0.001
|
< 0.001
|
< 0.001
|
< 0.001
|
0.001
|
< 0.001
|
|
Hair
|
|
Patients
|
195.43 ± 202.25
|
29.25 ± 16.44
|
34.26 ± 20.82
|
12.05 ± 12.95
|
18.87 ± 11.95
|
0.13 (0–2.16)
|
1.35 (0–91.46)
|
|
Control
|
198.23 ± 133.16
|
13.29 ± 26.54
|
53.00 ± 48.00
|
14.93 ± 35.01
|
12.57 ± 26.58
|
0 (0–0.21)
|
0 (0–0.01)
|
|
P value
|
0.96
|
0.002
|
0.012
|
0.558
|
0.132
|
0.001
|
0.007
|
|
Nails
|
|
Patients
|
294.65 ± 158.94
|
30.21 ± 16.70
|
32.85 ± 18.08
|
17.70 ± 12.08
|
15.72 ± 10.14
|
0.24 (0–2.64)
|
0.84 (0–9)
|
|
Control
|
338.80 ± 212.27
|
13.64 ± 30.55
|
20.07 ± 35.56
|
8.71 ± 26.27
|
52.57 ± 44.26
|
0 (0–0.45)
|
0.35 (0–0.69)
|
|
P value
|
0.353
|
0.003
|
0.034
|
0.032
|
< 0.001
|
0.002
|
0.514
|
- TAs: total arsenic; iAsIII%: inorganic arsenite/TAs × 100%; iAsV%: inorganic arsenate/TAs × 100%; MMA%: monomethylarsonic acid/TAs × 100%; DMA%: dimethylarsinic acid/TAs × 100%; PMI: primary methylation index; SMI: secondary methylation index
